Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Recruiting 2Unknown 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 41Metastatic Castration-resistant Prostate Cancer 4Prostatic Diseases 3Kidney Neoplasms 3Urogenital Neoplasms 2Prostatic Neoplasms, Castration-Resistant 2Neoplasms by Site 2Neoplasms 2Genital Neoplasms, Male 2Carcinoma, Renal Cell 2Thrombocytopenia 1Renal Insufficiency 1Prostate Cancer Metastatic 1PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy 1Neoplasm Metastasis 1Metastatic Hormone Naive Prostate Cancer 1Metastatic Castration Resistant Prostate Cancer (mCRPC) 1Metastatic Castration Resistant Prostate Cancer 1Metastatic Castrate Resistant Prostate Cancer (mCRPC) 1Male Urogenital Diseases 1Liver Neoplasms 1High-Risk Localized Prostate Cancer 1Glioma 1Glioblastoma 1Genital Diseases, Male 1Disease 1Cytopenia 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Hepatocellular 1Carcinoma 1

Interventions

padeliporfin 5darolutamide 3Pluvicto 3enzalutamide 2apalutamide 2Radiotherapy 2Nivolumab 2Androgen Antagonists 2Abiraterone Acetate 2talazoparib 1sipuleucel-T 1palladium-bacteriopheophorbide 1onapristone 1olaparib 1niraparib 1luprolide acetate gel depot 1ixabepilone 1gedatolisib 1gallium 68 PSMA-11 1abiraterone 1Therapeutics 1Tamsulosin 1Standard of Care 1Robotic Surgical Procedures 1Prostate-Specific Antigen 1Prednisone 1Paclitaxel 1Oxygen 1Nitrous Oxide 1Microtubule-Associated Proteins 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Prostatic Diseases × Pluvicto × Clear all
NCT06785636 2026-04-24

P300

Pathos AI, Inc.

Phase 1/2 Recruiting
252 enrolled
Genitourinary

Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT06496581 2024-12-20

Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

UNICANCER

Phase 3 Recruiting
500 enrolled
Genitourinary

Genital Diseases, Male, Prostatic Diseases

NCT05150236 2023-12-15

ANZUP2001

Australian and New Zealand Urogenital and Prostate Cancer Trials Group

Phase 2 Unknown
93 enrolled
Genitourinary

Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡